MARKET OUTLOOK<\/p>\n
U.S. gastroenterologists generally follow a step-up approach when treating Crohn\u2019s disease patients that begins with safe, albeit often less-efficacious, therapies (e.g., aminosalicylates) first line, before progressing to more-potent drugs, such as immunosuppressants and\/or biologics. Among the biologics, the TNF-alpha inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira), have\u2014and continue to be\u2014the most widely used agents. However, over the past two years, the Crohn\u2019s diseases treatment landscape has witnessed the approval of two novel biologics (i.e., Takeda\u2019s Entyvio and Janssen\u2019s Stelara), leading to increasing competition among the biologics, and further expanding physicians\u2019 treatment armamentarium.<\/p>\n
QUESTIONS ANSWERED<\/p>\n
What patient share do key therapies and brands garner by line of therapy in newly diagnosed Crohn\u2019s disease patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed Crohn\u2019s disease patients?
\nHow have Entivyo and Stelara been integrated into the treatment algorithm? \u00b7
\nWhat proportion of Crohn\u2019s disease patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
\nWhat percentage of Crohn\u2019s disease patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies? \u00b7
\nWhat are the product-level compliance and persistency rates among drug-treated patients with Crohn\u2019s disease?
\nPRODUCT DESCRIPTION<\/p>\n
Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390937","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390937\/revisions"}],"predecessor-version":[{"id":394061,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390937\/revisions\/394061"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}